David D. Ho
- Virology top 0.01%
- HIV Research and Treatment 211
- Infectious Diseases top 0.01%
- HIV/AIDS drug development and treatment 111
- HIV/AIDS Research and Interventions 73
- SARS-CoV-2 and COVID-19 Research 62
- Immunology top 0.02%
- Immune Cell Function and Interaction 79
- T-cell and B-cell Immunology 27
- T-cell and Retrovirus Studies 23
- Epidemiology top 0.05%
- Hepatology top 0.2%
-
- Monoclonal and Polyclonal Antibodies Research 30
David D. Ho
347 papers receiving 52.5k citations
Hit Papers
Peers
Comparison fields: 5 of 198
- Virology 38.3k
- Infectious Diseases 27.4k
- Immunology 19.2k
- Epidemiology 10.9k
- Hepatology 2.5k
Countries citing papers authored by David D. Ho
This map shows the geographic impact of David D. Ho's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David D. Ho with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David D. Ho more than expected).
Fields of papers citing papers by David D. Ho
This network shows the impact of papers produced by David D. Ho. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David D. Ho. The network helps show where David D. Ho may publish in the future.
Co-authorship network
The 25 scholars most cited alongside David D. Ho, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 2 | |
| 2 | 2025 | 3 | |
| 3 | 2025 | 0 | |
| 4 | 2024 | 3 | |
| 5 | 2024 | 4 | |
| 6 | XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1breakdown → | 2024 | 80 |
| 7 | 2023 | 20 | |
| 8 | 2023 | 13 | |
| 9 | 2023 | 12 | |
| 10 | 2023 | 11 | |
| 11 | Antibody evasion properties of SARS-CoV-2 Omicron sublineagesbreakdown → | 2022 | 478 |
| 12 | Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5breakdown → | 2022 | 433 |
| 13 | Multiple pathways for SARS-CoV-2 resistance to nirmatrelvirbreakdown → | 2022 | 260 |
| 14 | 2021 | 8 | |
| 15 | 2021 | 41 | |
| 16 | 2020 | 15 | |
| 17 | 2018 | 57 | |
| 18 | 2014 | 120 | |
| 19 | 1992 | 29 | |
| 20 | 1986 | 25 |
About David D. Ho
David D. Ho is a scholar working on Virology, Infectious Diseases and Immunology, having authored 350 papers that have together received 54.2k indexed citations. Recurring topics across this work include HIV Research and Treatment (211 papers), HIV/AIDS drug development and treatment (111 papers), Immune Cell Function and Interaction (79 papers), HIV/AIDS Research and Interventions (73 papers), SARS-CoV-2 and COVID-19 Research (62 papers), Monoclonal and Polyclonal Antibodies Research (30 papers), T-cell and B-cell Immunology (27 papers) and T-cell and Retrovirus Studies (23 papers). The work is most often cited by research in Virology (38.3k citations), Infectious Diseases (27.4k citations) and Immunology (19.2k citations). David D. Ho has collaborated with scholars based in United States, China and Hong Kong. Frequent co-authors include Martin Markowitz, Alan S. Perelson, Avidan U. Neumann, John M. Leonard, Linqi Zhang, Tarsem Moudgil, Yunzhen Cao, John P. Moore, Arlene Hurley and Yaoxing Huang. Their work appears in journals such as Journal of Virology, AIDS Research and Human Retroviruses, Science, Nature and The Journal of Infectious Diseases.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.